Although there are no data on the possible relationship between HMGA1 expression and clinical outcome in patients suffering from NBL, published studies on other cancer types suggest that HMGA1 overexpression is associated with aggressive tumor behavior and poor prognosis: such findings were reported for breast carcinoma (32–34), pancreatic adenocarcinoma (35), esophageal squamous cell carcinoma (36), non-small cell lung cancer (37), and uveal melanomas (38). Here, HMGA1 is linked to esophageal squamous cell carcinoma.